Cargando…

Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review article

BACKGROUND: Optimal antithrombotic therapy depicts a challenge to clinicians treating atrial fibrillation (AF) patients who are undergoing percutaneous coronary intervention (PCI). Theoretically, these patients would require a combination therapy of oral anticoagulant and dual antiplatelet therapy (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alshahrani, Ali, O’Nunain, Sean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462590/ https://www.ncbi.nlm.nih.gov/pubmed/37639078 http://dx.doi.org/10.1186/s43044-023-00402-0

Ejemplares similares

Safety and Efficacy of Bioresorbable Vascular Scaffolds in Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis
por: Alsinbili, Ahmed, et al.
Publicado: (2022)

Cardiovascular and bleeding risks of inactive cancer in patients with acute myocardial infarction who received primary percutaneous coronary intervention using drug-eluting stent and dual/triple antithrombotic therapy
por: Hayashi, Hiroya, et al.
Publicado: (2022)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Are Drug Eluting Stents Worth Triple Therapy?
por: Heidenreich, Paul
Publicado: (2017)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Is breast cancer surgery safely performed in patients receiving antithrombotic therapy?
por: Emoto, Norio, et al.
Publicado: (2017)

Harnessing Whole Genome Polygenic Risk Scores to Stratify Individuals Based on Cardiometabolic Risk Factors and Biomarkers at Age 10 in the Lifecourse—Brief Report
por: Richardson, Tom G., et al.
Publicado: (2022)

Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report
por: Shoji, Keisuke, et al.
Publicado: (2021)

Revisiting endovascular treatment in below-the-knee disease. Are drug-eluting stents the best option?
por: Spiliopoulos, Stavros, et al.
Publicado: (2018)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Ureteral stent technology: Drug-eluting stents and stent coatings
por: Yang, Luo, et al.
Publicado: (2015)

Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF
por: Kozieł, Monika, et al.
Publicado: (2021)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Ticagrelor: A safe option as part of triple therapy?
por: Farooq, Mohammad Umar
Publicado: (2020)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Drug-eluting metallic stents in urology
por: Kallidonis, Panagiotis S., et al.
Publicado: (2014)

Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis
por: Chen, Yun-lin, et al.
Publicado: (2019)

Estrogen-Eluting Stents
por: Ryu, Sung Kee, et al.
Publicado: (2009)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Optimization of Drug Delivery by Drug-Eluting Stents
por: Bozsak, Franz, et al.
Publicado: (2015)

Advances in drug eluting stents – focus on the Endeavor(®) zotarolimus stent
por: Bridges, Jonathan, et al.
Publicado: (2008)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new‐generation drug‐eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)‐4 trial
por: Gong, Xiaoxuan, et al.
Publicado: (2023)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
por: Whitbeck, Matthew G., et al.
Publicado: (2013)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy
por: Bond, Andrew J, et al.
Publicado: (2005)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

Drug-Eluting Stent: A Review and Update
por: Htay, Thein, et al.
Publicado: (2005)

Pathological Perspective of Drug-Eluting Stent Thrombosis
por: Inoue, Katsumi
Publicado: (2012)

Functional Nanoarchitectures For Enhanced Drug Eluting Stents
por: Saleh, Yomna E., et al.
Publicado: (2017)

Drug-eluting stents: insights into safety and indications
por: Hassan, Walid
Publicado: (2008)

Drug-Eluting Stents: Technical and Clinical Progress
por: Koźlik, Maciej, et al.
Publicado: (2023)

Comparisons of the Effects of Stent Eccentricity on the Neointimal Hyperplasia between Sirolimus-Eluting Stent versus Paclitaxel-Eluting Stent
por: Kim, Byeong-Keuk, et al.
Publicado: (2010)

Time‐trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF‐STENT Registry
por: Boivin‐Proulx, Laurie‐Anne, et al.
Publicado: (2019)

The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2022)

Antithrombotic Management in AF Patients Following Percutaneous Coronary Intervention: A European Perspective
por: Greco, Antonio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4ksaopi6u2ncf6jr0ndo5qrcei